ClinicalTrials.gg
CompletedNCT06144710Updated Aug 11, 2026

SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

A Phase 1 interventional study of SG301 SC Injection and SG301 SC Placebo in Systemic Lupus Erythematosus (SLE), sponsored by Hangzhou Sumgen Biotech Co., Ltd.. Completed at 10 sites in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Hangzhou Sumgen Biotech Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Enrollment
102nd of 245
48 · median 36
Started
2023
with 23 others
Phase 1
109 of 266
85 open now
Registered
102nd of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 102nd largest by enrollment of the 245 interventional ones that give a count, is one of 24 that started in 2023, is one of 109 in phase 1, and was the 102nd registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single dose in healthy volunteers and multiple doses of SG301 SC injection in participants with systemic lupus erythematosus (SLE).

Read the detailed description

This is a phase I single ascending dose (SAD) study in healthy volunteers and multiple ascending dose (MAD) study in participants with mild or moderate SLE, which consists of Parts A and B. Part A adopts a single-center, open-label, dose escalation trial design, and Part B adopts a multi-center, randomized, double-blind, placebo-controlled trial design to evaluate the safety, tolerability, PK, and immunogenicity, preliminary efficacy of SG301 SC Injection in patients with mild to moderate SLE.

03

Conditions studied

  • Systemic Lupus Erythematosus (SLE)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A (healthy volunteers)

  1. Male healthy adults aged 18-50 years (inclusive);
  2. Male participants weighed 50-100 kg (inclusive) with the of 19.0-27.0 kg/m2 (inclusive);
  3. Participants whose partners are of must agree to use effective methods throughout the study period and for 6 months following the last dose.

Part B (SLE participants)

  1. Males or females aged 18-65 years (inclusive);
  2. BMI 18.5-30.0 kg/m2 (inclusive);
  3. Have diagnosed as SLE based on the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria, with inadequate response or intolerance to or having despite the standard treatment;
  4. SELENA-SLEDAI score >4 and ≤12;
  5. Serologically ANA and/or anti-ds-DNA antibody tested positive;
  6. Having received a standard treatment for at least 12 weeks prior to the first dose that has remained at a stable dose for at least 4 weeks prior to the first dose;
  7. Laboratory values at screening meets the following criteria:

    1. Liver function: (AST) and alanine aminotransferase (ALT) ≤ 2ULN, total \<1.5×;
    2. Renal function: creatinine (Cr) and urea ≤1.5×ULN; >60 ml/min (calculated by the MDRD formula); urine total protein-creatinine ratio ≤3.0 g/g or 24h urine protein ≤3.5 g;
    3. Bone marrow function: ≥100g/L, WBC≥3.0×109/L, ≥75×109/L;
    4. Participants who are of childbearing potential or whose partners are of childbearing potential must agree to use effective contraceptive methods throughout the study period and for 6 months following the last dose.

Exclusion criteria

Exclusion Criteria:

Part A (healthy volunteers)

  1. Have a history of allergies or likely to be allergic to the drug or any of their ingredients judged by the investigators;
  2. Have previously received drugs of the same target (CD38);
  3. Have participated in a clinical trial of any drug or medical device within 3 months or 5 half-lives prior to dosing, whichever is longer;
  4. Have received any prescription drugs or Chinese herbal medicines within 4 weeks prior to dosing, or any non-prescription or dietary supplements within 2 weeks prior to dosing;
  5. Have infections within 2 weeks prior to first dose (including but not limited to viral, bacterial, or fungal infections);
  6. Have experienced symptomatic herpes zoster within 3 months prior to dosing;
  7. Presence of any of the following diseases assessed by the investigator as abnormal with clinical significance within 6 months prior to dosing;
  8. Have a history of cardiovascular diseases within 6 months prior to dosing: chronic congestive heart failure ( [NYHA] Class III or IV), myocardial infarction, severe heart diseases (e.g., unstable angina, cardiogenic shock, arrhythmias requiring treatment, heart valve diseases, hypertrophic cardiomyopathy, and rheumatic heart disease, etc.), and familial long syndrome, etc.;
  9. Presence of chronic nervous system symptoms such as dizziness and headache prior to dosing;
  10. Blood cell count below the lower limit of normal (LLN), or abnormalities in any other hematology tests within 1 week prior to dosing;
  11. (ALT) or aspartate aminotransferase (AST) >1.2×, total >1.2×ULN;
  12. abnormalities with clinical significance, e.g. QTcF >450 ms;
  13. Any vital signs abnormal with clinical significance;
  14. Fasting blood glucose above ULN;
  15. Any abnormal from physical examination, laboratory tests, or chest CT with clinical significance;
  16. surface antigen (HBsAg) or core antibody (HBcAb) positive, virus (HCV) antibody positive, TPPA positive, or antibody positive;
  17. Mycobacterium tuberculosis infection;
  18. Having received a live or attenuated within 4 weeks prior to dosing or planning to do so during the trial;
  19. Skin injection site abnormal, including but not limited to birthmarks, scars, black moles, tattoos, and open wounds;
  20. Blood donation ≥400 ml or blood loss ≥400 ml within 4 weeks prior to dosing, or having received blood transfusion within 8 weeks prior to dosing;
  21. A history of heavy drinking within 3 months prior to dosing;
  22. A history of drug abuse within 5 years prior to dosing or use of narcotics within 3 months prior to the trial.

Part B (SLE participants)

  1. Has a history of central nervous system disorders that require prohibited medicine treatment within 2 months prior to the first dose;
  2. Presence of concomitant rheumatic diseases within 12 months prior to the first dose, including but not limited to rheumatoid arthritis, spondyloarthritis, dermatomyositis/polymyositis, Sjogren's syndrome, systemic sclerosis, mixed connective tissue disease, and overlap syndrome, etc.;
  3. Presence of catastrophic antiphospholipid syndrome within 12 months prior to the first dose;
  4. Has a history of non-SLE inflammatory skin or joint disease within 12 months prior to the first dose;
  5. Presence of chronic active infection or acute infection within 4 weeks prior to first dose or superficial skin infection within 1 week prior to first dose;
  6. A known or suspected history of ;
  7. Have undergone a major surgery within 12 weeks prior to the first dose or having an unhealed wound, ulcer or fracture, or planning to undergo a major surgery during the study;
  8. Having participated in any clinical trial within 12 weeks prior to the first dose or have received other investigational products within 5 half-live, whichever is longer;
  9. Have received any drugs targeting T or B lymphocytes (e.g., rituximab) within 6 months or cytokines or cytokines receptors (e.g., belimumab, telitacicept, etc.) treatment within 5 half-lives prior to the first dose;
  10. Having received JAK inhibitors treatment within 12 weeks or 5 half-lives prior to the first dose, whichever is shorter;
  11. Having received any of the following treatment within 12 weeks prior to the first dose:

    1. Intravenous immunoglobulin (IVIG)
    2. Plasma exchange
    3. Intravenous cyclophosphamide;
  12. Have diseases with major clinical significance within 6 months prior to first dose, including but not limited to circulatory system disorders, endocrine system disorders, nervous system disorders, blood system disorders, immune system disorders, and psychiatric disorders, etc.;
  13. A history of cardiovascular diseases within 6 months prior to the first dose, including but not limited to chronic congestive heart failure (NYHA Class III or IV), myocardial infarction, severe heart diseases (e.g., unstable angina, cardiogenic shock, arrhythmias requiring treatment, heart valve diseases, hypertrophic cardiomyopathy, and rheumatic heart disease, etc.), QTcF >450 ms or familial long QT interval syndrome, poorly controlled hypertension;
  14. Mycobacterium tuberculosis infection;
  15. Presence of active hepatitis:

    1. HBsAg positive and/or HBcAb positive and HBV DNA positive;
    2. HCV antibody positive and HCV RNA positive;
  16. HIV antibody positive;
  17. Both TPPA and RPR positive;
  18. Known allergy to monoclonal antibody drugs or to any of the investigational drug;
  19. Having received a live or attenuated live vaccine within 4 weeks prior to the first dose or planning to do so during the study;
  20. Have a history of major organ transplantation or hematopoietic stem cell/ bone marrow transplantation;
  21. Have a history of within 5 years prior to first dose;
  22. Participants with depression or suicidal tendency;
  23. Have a history of heavy drinking or drug abuse within 3 months prior to first dose;
  24. Pregnant or breastfeeding women, or women who plan to become pregnant or may breastfeed during the study and for 6 months following the last dose; male participants whose partner plans to become pregnant during the study.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    SG301 SC

    Part A: Dose escalation of SG301 SC will be done in healthy volunteers at 1 mg/kg dose group and 2 mg/kg dose group. Part B: Dose escalation of SG301 SC will be done in Systemic lupus erythematosus subjects in 4 dose groups, namely 2 mg/kg, 4 mg/kg, 8 mg/kg, and 12 mg/kg dose groups. 8 subjects will be randomized to SG301 SC injection in an 8:2 ratio at each dose group.

    Drug: SG301 SC Injection

  • Placebo comparator
    Placebo

    Part B: Dose escalation of SG301 SC will be done in Systemic lupus erythematosus subjects in 4 dose groups, namely 2 mg/kg, 4 mg/kg, 8 mg/kg, and 12 mg/kg dose groups. 2 subjects will be randomized to SG301 SC injection in an 8:2 ratio at each dose group.

    Drug: SG301 SC Injection · Drug: SG301 SC Placebo

Interventions

  • Subcutaneous injection every two weeks

  • DrugSG301 SC Placebo

    Subcutaneous injection every two weeks

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events(Part A and Part B)

    Number and percentage of AEs which are calculated by worst CTCAE grade by CTCAE 5.

    Time frame: From baseline through the end of study. Part A: Average 2 months per subject, Part B: Average 5 months per subject.

Secondary outcomes

  1. RP2D (PartB)

    RP2D will be determined based on the DLTs and safety data.

    Time frame: From baseline through the end of study. Average 5 months per subject.

  2. Pharmacokinetics (PK): Cmax (Part A and Part B)

    Cmax to maximum drug concentration administration.

    Time frame: From baseline through the end of study. Part A: Average 2 months per subject, Part B: Average 5 months per subject.

  3. Pharmacokinetics (PK): limination half-life (T1/2) (Part A and Part B)

    Limination half-life (T1/2) of the drug after administration.

    Time frame: From baseline through the end of study. Part A: Average 2 months per subject, Part B: Average 5 months per subject.

  4. Immunogenicity (Part A and Part B)

    Anti-SG301 antibody (ADAdrug), neutralizing antibody (Nabdrug, to be detected only in case of the presence of ADAdrug), and anti-hyaluronidase antibody (ADArHu).

    Time frame: From baseline through the end of study. Part A: Average 2 months per subject, Part B: Average 5 months per subject.

  5. PD endpoints: CD38 RO (Part B)

    Detect the CD38 RO

    Time frame: From baseline through the end of study. Average 5 months per subject.

  6. Biomarkers evaluation (Part B)

    It includes anti-ds-DNA autoantibody and complement factors C3 and C4.

    Time frame: From baseline through the end of study. Average 5 months per subject.

  7. Efficacy evaluation (Part B)

    Activity will be evaluated by SELENA SLEDAI.

    Time frame: From baseline through the end of study. Average 5 months per subject.

  8. Evaluation of exploratory measures:immunoglobulins (Part B)

    Changes from baseline in immunoglobulins IgG, IgM and IgA with the investigational drug SG301 SC Injection and SG301 SC placebo.

    Time frame: From baseline through the end of study. Average 5 months per subject.

  9. Evaluation of exploratory measures:BILAG-2004 /PGA (Part B)

    Changes from baseline in BILAG-2004 and PGA with the investigational drug SG301 SC Injection and SG301 SC placebo.

    Time frame: From baseline through the end of study. Average 5 months per subject.

  10. Evaluation of exploratory measures:immune cell (Part B)

    Changes from baseline in the immune cell subsets including NK cells (activated and total), B cell subsets, plasmacytes, and plasmablasts, etc.

    Time frame: From baseline through the end of study. Average 5 months per subject.

07

Study locations

10 sites
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui 233000, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350004, China
  • First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
  • Shenzhen People's Hospital
    Shenzhen, Guangdong 518020, China
  • Jiangxi Provincial People's Hospital
    Nanchang, Jiangxi 330006, China
  • Pingxiang People's Hospital
    Pingxiang, Jiangxi 337099, China
  • Shandong University Qilu Hospital
    Jinan, Shandong 250063, China
  • Jining First People's Hospital
    Jining, Shandong 272002, China
  • Huashan Hospital affiliated to Fudan University
    Shanghai, Shanghai Municipality 200040, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang 314408, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jan 2026, 25 months.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's 25 months is below that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2023
First posted
Nov 22, 2023
StartActual
Nov 10, 2023
Primary completionActual
Jan 7, 2026
CompletionActual
Jan 7, 2026
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06144710
Responsible party
Sponsor
First posted
Nov 22, 2023
Start date
Nov 10, 2023
Primary completion
Jan 7, 2026
Completion
Jan 7, 2026
Last update
Aug 11, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sanritatug

Start the discussion